HR 756, a New Cephalosporin Active Against Gram-Positive and Gram-Negative Aerobic and Anaerobic Bacteria | Zendy

Harold C. Neu | Zendy; Nalinee Aswapokee | Zendy; P Aswapokee | Zendy; Kwung P. Fu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HR 756, a New Cephalosporin Active Against Gram-Positive and Gram-Negative Aerobic and Anaerobic Bacteria

Author(s) -

Harold C. Neu,

Nalinee Aswapokee,

P Aswapokee,

Kwung P. Fu

Publication year - 1979

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.15.2.273

Subject(s) - microbiology and biotechnology , bacteroides fragilis , proteus mirabilis , cefoxitin , carbenicillin , enterobacter , klebsiella pneumoniae , pseudomonas aeruginosa , enterobacter cloacae , cephalosporin , staphylococcus aureus , enterobacteriaceae , shigella flexneri , ampicillin , escherichia coli , haemophilus influenzae , peptostreptococcus , biology , klebsiella , anaerobic bacteria , antibiotics , bacteria , biochemistry , genetics , gene

The in vitro activity of HR 756, 7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoximino)acetamido] cephalosporanic acid, was investigated against 659 isolates. HR 756 inhibitedNeisseria andHaemophilus species at concentrations similar to those needed with ampicillin. It inhibited β-lactamase-producingN. gonorrhoeae andH. influenzae . HR 756 was the most active compound tested against members of theEnterobacteriaceae , inhibiting most isolates ofEscherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella, Enterobacter , andShigella at concentrations of less than 0.1 μg/ml. It was twice as active as carbenicillin againstPseudomonas aeruginosa and inhibitedBacteroides fragilis as well as cefoxitin. HR 756 killedE. coli, Staphylococcus aureus , andP. aeruginosa at rates similar to other β-lactam antibiotics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research